Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911343 | 0.79 | L3MBTL1 (0.45) | L3MBTL1KMT2AALDH1A1MMP1MMP2 | |
| SCHEMBL6911348 | 0.79 | L3MBTL1 (0.45) | L3MBTL1KMT2AALDH1A1MMP1MMP2 | |
| SCHEMBL6911352 | 0.77 | L3MBTL1 (0.42) | L3MBTL1CYP19A1KMT2ALMNAFAAH | |
| SCHEMBL6925847 | 0.71 | MMP2 (0.58) | L3MBTL1KMT2ALMNAALDH1A1MMP1 | |
| SCHEMBL6397464 | 0.69 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1 | |
| SCHEMBL8548451 | 0.69 | CA2 (0.68) | CYP19A1KMT2ALMNAALDH1A1MMP1 | |
| SCHEMBL7211717 | 0.67 | KMT2A (0.63) | KMT2AFAAHALDH1A1MMP1MMP2 | |
| SCHEMBL23703023 | 0.67 | ALDH1A1 (0.61) | L3MBTL1CYP19A1KMT2ALMNAFAAH | |
| SCHEMBL4636140 | 0.65 | SMN1; SMN2 (0.50) | L3MBTL1 | |
| SCHEMBL6912836 | 0.65 | GAA (0.53) | KMT2ALMNAALDH1A1MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | L3MBTL1 3997/4885CYP19A1 1856/4885KMT2A 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.